CEP
SUPN icon

Chicago Equity Partners’s Supernus Pharmaceuticals SUPN Stock Holding History

Chicago Equity Partners’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-26,940
Closed -$639K – 853
2019
Q4 		$639K Sell
26,940
-26,405
-49% -$641K 0.04% 583
2019
Q3 		$1.47M Sell
53,345
-31,975
-37% -$947K 0.07% 395
2019
Q2 		$2.82M Sell
85,320
-615
-0.7% -$21.1K 0.13% 229
2019
Q1 		$3.01M Hold
85,935
– – 0.12% 241
2018
Q4 		$2.85M Sell
85,935
-3,370
-4% -$145K 0.12% 260
2018
Q3 		$4.5M Buy
89,305
+2,965
+3% +$146K 0.13% 207
2018
Q2 		$5.17M Buy
+86,340
New +$4.47M 0.16% 178

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Chicago Equity Partners's SUPN Position: Q1 2020 in Review

Chicago Equity Partners sold out of Supernus Pharmaceuticals (SUPN) in Q1 2020, closing a stake of 26,940 shares — an estimated $639K sold.

Chicago Equity Partners first reported a position in SUPN in Q2 2018 and held it in 7 quarters. The position peaked at $5.17M in Q2 2018. 208 funds tracked by Wall St. Rank hold SUPN as of Q1 2020.

  • Chicago Equity Partners reported no remaining Supernus Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Chicago Equity Partners sold 26,940 Supernus Pharmaceuticals shares in Q1 2020, an estimated $639K.
  • Chicago Equity Partners first reported a position in Supernus Pharmaceuticals in Q2 2018 and held it in 7 quarters.
  • Chicago Equity Partners's Supernus Pharmaceuticals position peaked at $5.17M in Q2 2018.
  • 208 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2020.

Based on Chicago Equity Partners's 13F filing for Q1 2020, filed 6 May 2020.